drugset / Trial / NCT00343226

An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in "de Novo" Liver Transplantation.

NCT00343226

Phase 4 Completed 48 enrolled Novartis
RandomizedParallel-groupOpen-labelTreatment

Summary

The objectives of the study are:To compare the renal function of a quadruple immunosuppressive regimen (including basiliximab in combination with an optimized cyclosporine dose during the first weeks post-transplantation, mycophenolate mofetil and corticosteroids) versus a standard triple therapy regimen (including cyclosporine standard dose, mycophenolate mofetil and corticosteroids)

Timeline

Start
2002-05
Primary completion
2005-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Basiliximab Monoclonal antibody

Indications

No indication recorded.